Imugene is an Australian clinical-stage immuno-oncology company based in Sydney. It develops cancer immunotherapies and oncolytic virus treatments designed to stimulate the body's immune system to attack tumours. Its pipeline includes modified oncolytic virus candidates and cancer vaccines aimed at a range of solid tumours. The company works with clinical investigators and research partners to test these therapies in patients, and its work is directed at oncology treatment rather than at consumer or industrial markets.
Imugene Ltd trades under the code IMU on the Australian Securities Exchange in Australia, with its price quoted in Australian dollars (AUD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Market X-Ray · price-based
Weak price profile
Ranks #1698 of 1815 on the Australian Securities Exchange · confidence High
What this score is, and is not
It describes how this stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is. That fundamental X-Ray needs financial statements, which we do not have for Australia yet.
TrendWeak
1/100
Below its long-term averages and far from its highs.
See the numbers →
Above 200-day average-72.5%
From 52-week high-90.9%
MomentumWeak
1/100
Lagging most stocks on this exchange.
See the numbers →
3-month return-58.9%
6-month return-71.5%
12-month, skipping last month-88.7%
Stability (higher is calmer)Weak
18/100
Volatile, with deep drawdowns.
See the numbers →
Volatility, 1 year (lower is calmer)90.0%
Worst drawdown, 1 year (smaller is calmer)-91.6%
LiquidityFair
65/100
Moderate trading activity.
See the numbers →
Avg daily value traded0.15M AUD
Zero-volume days0.0%
IncomeNone
–/100
Pays no dividend.
See the numbers →
Years with dividends0
Price-based X-Ray. The fundamental X-Ray (financial health, valuation, growth, fair value) is available for US stocks today. It will follow for Australia when fundamentals data for this market is added. All Australia stocks.
52-wk range 0.032 – 0.430Daily closes, split-adjusted
Signals
50-day average0.055
200-day average0.135
Golden/death cross (60d)None
New 52-week highNo
Bullish RSI divergenceYes
Average daily range (ATR)0.004
Technical summary
Daily
Strongly bearish
0 bullish · 4 neutral · 12 bearish
Weekly
Strongly bearish
1 bullish · 0 neutral · 11 bearish
Monthly
Strongly bearish
1 bullish · 0 neutral · 7 bearish
Moving averages (daily)
SMA 10
0.04
Bearish
EMA 10
0.04
Bearish
SMA 20
0.04
Bearish
EMA 20
0.04
Bearish
SMA 50
0.06
Bearish
EMA 50
0.05
Bearish
SMA 100
0.08
Bearish
EMA 100
0.08
Bearish
SMA 200
0.13
Bearish
EMA 200
0.16
Bearish
Oscillators (daily)
RSI (14)
35.98
Neutral
MACD (12, 26)
-0.01
Bearish
Momentum (12)
-13.95
Bearish
Stochastic %K (14)
27.78
Neutral
Williams %R (14)
-72.22
Neutral
CCI (20)
-76.69
Neutral
Pivot points (classic, last session)
S3
0.03
S2
0.03
S1
0.04
Pivot
0.04
R1
0.04
R2
0.04
R3
0.04
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Prices are end-of-day closes in AUD. Educational only, not financial advice.
